Nephros (NASDAQ:NEPH) Earns Speculative Buy Rating from Benchmark

Nephros (NASDAQ:NEPH)‘s stock had its “speculative buy” rating reissued by research analysts at Benchmark in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $5.00 price objective on the stock. Benchmark’s target price would indicate a potential upside of 206.75% from the stock’s previous close.

Nephros Price Performance

Shares of Nephros stock opened at $1.63 on Tuesday. Nephros has a 1-year low of $1.36 and a 1-year high of $4.04. The company has a market capitalization of $17.18 million, a P/E ratio of -18.11 and a beta of 1.19. The business’s fifty day moving average price is $1.62 and its two-hundred day moving average price is $1.93.

Institutional Investors Weigh In On Nephros

A hedge fund recently bought a new stake in Nephros stock. Dimensional Fund Advisors LP purchased a new position in Nephros, Inc. (NASDAQ:NEPH) in the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 17,631 shares of the company’s stock, valued at approximately $37,000. Dimensional Fund Advisors LP owned 0.17% of Nephros at the end of the most recent quarter. Institutional investors and hedge funds own 41.10% of the company’s stock.

Nephros Company Profile

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.